Two Years of Ocrelizumab Treatment in Black and Hispanic People with Multiple Sclerosis in CHIMES: A Single-Arm Clinical Trial.
Ann NeurolJul 30, 2026 (epub)
Clinical ResearchNeurology
Lilyana Amezcua, Anthony T Reder, Evanthia Bernitsas et al.
✦ AI-curated · Sources linked
In 30 seconds
The CHIMES trial evaluated the effectiveness and safety of ocrelizumab in black and Hispanic individuals with relapsing multiple sclerosis. This single-arm, phase 4 study included 182 participants aged 18-65 years. At week 48, 50.5% of participants had no evidence of disease activity, with 94.5% free from confirmed disability progression.
Key findings
- 50.5% of participants had no evidence of disease activity at week 48.
- 94.5% were free from 24-week confirmed disability progression.
- Infusion-related reactions occurred in 42.0% of Hispanic participants compared to 29.2% of black participants.
- Serious adverse events were reported by 8.2% of participants.
Why it matters
This study highlights the effectiveness of ocrelizumab in underrepresented populations, providing important data on its safety and efficacy in managing relapsing multiple sclerosis among black and Hispanic patients.